Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the initial agreement, Asahi Kasei Pharma received exclusive rights to develop and commercialize Basilea’s antifungal Cresemba (isavuconazole), an intravenous and oral azole antifungal, in Japan.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Basilea Pharmaceutica
Deal Size: $72.3 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement March 23, 2023
Details:
Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.
Lead Product(s): Apraglutide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: VectivBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.
Lead Product(s): VEL-101
Therapeutic Area: Immunology Product Name: FR104
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Veloxis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-host disease in Japan.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: VectivBio
Deal Size: $200.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement March 30, 2022
Details:
Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Basilea Pharmaceutica
Deal Size: $72.3 million Upfront Cash: $7.5 million
Deal Type: Partnership September 30, 2021
Details:
The phase 3, multi-center, open-label study enrolled 103 patients and was assessing the safety and efficacy of intravenously or orally administered isavuconazole for the treatment of adult Japanese patients suffering from deep-seated mycoses.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Basilea Pharmaceutica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.
Lead Product(s): AK1780
Therapeutic Area: Neurology Product Name: AK1780
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $410.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement January 29, 2021
Details:
The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021